For hematologic malignancies, CD33 and CLEC12A (AML), BCMA, and CD38 (MM), and CD30 (PTCL) are targeted as tumor arms [110,111]. The gene discussed is TNFRSF17; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.